Background:
Introduction

Scope of the clinical problem
Coronary artery disease (CAD) remains one of the leading causes of death globally among adult males and females alike (1). Stable chest pain symptoms (also referred to as stable angina) is an important manifestation of CAD. The lifetime risk of developing CAD depends on age, gender, ethnicity, geographic region and the presence of cardiovascular risk factors and is estimated to be 38-51% in men and 12-33% in women (2) . For patients who newly present with stable chest pain symptoms the evaluation of suspected CAD commonly includes a diagnostic workup to investigate for the presence of CAD. The evaluation should always begin with an appropriate history and physical examination. Catheter-based coronary angiography (CAG), at times combined with catheter-based fractional flow reserve (FFR) measurements, is the reference standard to diagnose functionally significant CAD. Since it is costly, invasive, and associated with a substantial risk of major adverse events, CAG is recommended as initial test for patients with a high prior probability of CAD (3).
However, research has shown that only 41% of patients undergoing elective procedures of catheter based coronary angiographies are diagnosed with obstructive CAD (4). This stresses the need for better risk stratification, which is underlined by decision analyses showing that the optimal choice of further diagnostic investigation in patients with stable chest pain depends primarily on the prior probability of CAD (5) (6) (7) . Deciding on subsequent diagnostic testing in patients with suspected CAD is however difficult, partly because of the many testing options currently available. 5 that has been in widespread clinical use for decades to determine the presence of significant CAD.
In clinical practice, cardiac imaging strategies are used when ECG abnormalities during xECG are nondiagnostic and when it is important to determine the extent and distribution of ischaemic myocardium. In addition, cardiac imaging strategies are used to exclude or confirm a positive or negative xECG as well as to decide whether a patient requires CAG (8) .
Owing to the rapid technological advancement in cardiovascular diagnostic imaging, many noninvasive diagnostic tests are currently available which either evaluate coronary anatomy or the presence of inducible myocardial ischaemia (functional ischaemia testing), or both. CT coronary angiography (CTCA) evaluates coronary anatomy. Tests evaluating the presence of inducible myocardial ischaemia include stress echocardiography (SE), stress perfusion cardiac magnetic resonance imaging (CMRI), and myocardial perfusion imaging (MPI), i.e. myocardial perfusion scintigraphy (MPS) (either single-photon emission computed tomography [SPECT] or positronemission tomography [PET] ). Furthermore, FFR can now be estimated from acquired computed tomography data (FFRct) based on computational fluid dynamics (9) . Yet, although these tests are relatively non-invasive compared to catheter-based CAG, it should be noted that they still pose a burden to the individual patient, the health care system, and society at large, because they are associated with significant patient time, costs, radiation exposure and the risk of adverse events.
Compounding the problem, physicians often request multiple tests in order to increase their confidence in the diagnosis and treatment plan of patients presenting with stable chest pain.
Diagnostic imaging algorithms
In order to minimise risks and burden to patients, radiation exposure and health care costs, diagnostic algorithms have been developed to optimise the diagnostic workup. These algorithms define a combination and sequence of tests, where the choice of each imaging test is determined by patient characteristics and the results of previously performed diagnostic tests. Imaging algorithms recommended by guidelines vary widely, demonstrating variability in clinical practice and attesting to by guest on June 9, 2016 http://ehjqcco.oxfordjournals.org/ Downloaded from the uncertainty about which algorithm is optimal (3, 10, 11). For example, the American College of Cardiology/American Heart Association and European Society of Cardiology recommend exercise electrocardiography to select patients for further diagnostic investigation, while the UK guidelines recommend using the computed tomography (CT) based coronary calcium score (CACS) in patients with a low to intermediate prior probability (10-29%) (11, 12) . It has yet to be elucidated which imaging algorithm is optimal in terms of both costs and outcomes, i.e. is cost-effective.
Purpose of this study
In this paper we present a systematic review of available evidence on cost-effectiveness of currently available non-invasive imaging tests and imaging algorithms for the diagnostic workup of patients with stable chest pain symptoms who are suspected of having obstructive CAD.
Materials and methods
In a systematic literature search, we identified original articles that economically evaluated noninvasive cardiac imaging strategies. We searched the electronic databases PubMed as publisher, Medline (OvidSP), Embase, Web of Science, Cochrane economic evaluations library and EconLit. The search included keywords corresponding to the index tests (CTCA, SE, MPS, PET, SPECT, CMRI, CACS, xECG, FFR), the reference test (CAG), the target condition CAD and cost-effectiveness. We used various synonyms including both text words and Medical Subject Headings (MeSH) terms to maximise the sensitivity of our search.
We restricted our search to papers in English language published during the last 20 years (between January 1995 and December 2015) to identify economic evaluations studies and decision models with respect to non-invasive cardiac imaging tests. We only included papers dealing with adult patients presenting with chest pain symptoms suggesting the presence of stable CAD. Studies were excluded if the target condition was suspected acute coronary syndrome. We also excluded guidelines and studies focusing on detecting high risk (left main and triple vessel) CAD only, however, the references were checked for additional papers.
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We included studies if they met all of the following criteria: the study (1) performed a formal economic evaluation or decision analysis, (2) provided a thorough accounting of costs or evaluated both costs and effectiveness, (3) demonstrated total cost differences or reported either cost savings and increased effectiveness (= defined as dominance) or cost increases and gains in (quality adjusted) life year ([QA]LY) or healthy-year equivalents. Full-texts of articles containing the search terms in the title and/or abstract were selected by two reviewers independently (C.N.v.W. and M.Y.K.). Articles were excluded if both reviewers agreed they were ineligible. Discrepancies were resolved by consensus. Data of the included full texts on authors, reference, journal, year of publication, time horizon, perspective, country, imaging modalities compared, type of model, data sources, currency (type and year), threshold willingness-to-pay, reference case analysis, reference case result, suggested imaging strategy for low-intermediate prior probability of CAD, sensitivity analysis, influential input parameters, and generalisability were extracted by one reviewer (C.N.v.W.).
Extracted data were checked for accuracy by a second reviewer (T.G.). Discrepancies were resolved by consensus. The quality of included studies was assessed by one reviewer (C.N.v.W.) using a modified version of the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist (13) (see appendix table 4), as recommended by published guidelines (14, 15) .
Data synthesis
Given the heterogeneity of the data, no formal quantitative pooling of results was performed.
Synthesis of the data was performed qualitatively, and clinical implications are drawn. To enhance comparability, results were adjusted from the original papers by rounding the numbers and using a reporting format as recommended by reporting standards for cost-effectiveness analyses. Therefore, the data presented here may be different from the data reported in the original papers. Reported incremental cost-effectiveness ratios (ICERs) were recalculated from the reported data to ensure a correct comparison across the diagnostic imaging strategies.
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Furthermore, a few studies (n=8/ 11%) used a Bayesian mathematical simulation model. The earlier mathematical simulation models, such as the one by Patterson et al 1995 (16) , focused on diagnostic accuracy statistics as drivers for evaluating economic efficiency. In fact, these models were built on the principles of minimising costs through higher sensitivity and lower false-positive rates. Although these models rely on unrealistic assumptions, such as 100% of the patients with abnormal tests proceeding to CAG, they provide some insight into potentially cost-effective strategies and formed groundwork for several recent mathematical simulation models. The majority (n=35 / 50%) of studies however, used methods to look at costs only (n=17) or used miscellaneous methods to look both at costs and effectiveness (n=18). Some of these studies used costs per correct diagnosis as outcome (n=5) making them incomparable to cost/QALY cost-effectiveness studies.
Looking at the willingness-to-pay (WTP) threshold, i.e. what society should be paying for a gain in effectiveness, many studies do not report a WTP threshold since they look only at costs or use short term outcomes. Few studies do report a WTP threshold (n=12/ 17%), however there is no international consensus on which WTP threshold to use and this threshold thus varies across countries, ranging from £10.000-€80.000/QALY. Additionally, we found considerable variability in the reporting of cost data (see appendix table 9) as well as in the quoted costs of different tests depending on assumptions about patient volumes and whether bottom-up costs or prices have been used. Furthermore, we found that about two-third of the included studies performed sensitivity analysis (see table 1 ). Of these, sensitivity analyses showed that the optimal diagnostic imaging strategy depends mostly on the prior probability of CAD, test characteristics and costs of a test. Only a few studies (n=10 / 14%) modelled all parameter uncertainty simultaneously (probabilities, utilities and costs) with probabilistic sensitivity analysis. There are also important differences in the reference case analyses performed and algorithms compared. In most studies the reference case analysis was not stratified by gender, although men and women may be quite different given their age and prior probability for CAD (see appendix table   8 ). Arguably, only the study by Genders et al. 2015 (17) , considered most but not all possible imaging tests. In fact, a wide range of imaging strategies was compared across the studies included in this systematic review. CTCA-based strategies are commonly compared, while only few studies comparing PET-based strategies (see table 2 ). In addition, only few studies considered a 'no testing' strategy (n=9/ 13%). Further, only few studies compared functional and anatomical tests (n=20/ 29%). Most studies compared only functional tests (n=34/ 49%) and suppose SE to be superior over SPECT or CMRI. Furthermore, although potential cost savings are reported when SPECT-guided diagnostic strategies are compared with xECG-guided strategies, for example in a report by Marwick et al 2003 (18), it is not the case that SPECT is cost-effective when compared with other diagnostic imaging modalities (17) .
As can be seen from appendix table 5 and table 3 , for most patients who present with typical or atypical angina, performing a non-invasive diagnostic test is a reasonable use of health care
resources. Yet, as also can be seen from table 3, the cost-effectiveness of diagnostic strategies is strongly influenced by the prior probability of CAD. In 26 out of 32 studies considering CTCA, CTCA was cost-effective and suggested as a 'gatekeeper' (initial) test for adult patients with lowintermediate prior probability of CAD (10%-≤50%) and prior to cardiac stress imaging. Yet, the prior probability thresholds for CAD below which CTCA is suggested and above which SE or SPECT varied across studies. CMRI and SE were preferred over xECG as initial stress test, and SE was cost-effective compared to SPECT in patients with a low-intermediate prior probability. Coronary angiography was cost-effective in patients with a high prior probability of CAD (≥70%).
Discussion
We present a systematic review of the published evidence on the comparative cost-effectiveness of currently available non-invasive imaging tests for the diagnostic workup of patients with stable chest pain symptoms who are suspected of having CAD. Our findings indicate that, in a setting of low to intermediate prior probability, there is no simple answer to what the optimal diagnostic imaging strategy is for individuals who are suspected of having CAD, as this depends on several variables: costs of the tests, test characteristics, prior probability, society's willingness-to-pay threshold, optimisation criterion, availability of imaging tests, patient preference and local expertise.
Differences across studies
There are a number of differences across the included studies in our systematic review that should be recognised. Whereas the societal perspective is generally recommended in most countries, most studies took the perspective of the health care payer or health care provider (hospital). In addition, most studies used a short term time horizon for their analyses. Depending on the assumptions made, however, it is possible that long-term analyses produce results that are significantly different from those obtained with short-term analyses (19) . For this reason, it is hard to draw any definitive conclusions from the data presented in this systematic review. In addition, in most of the included studies the diagnostic performance of non-invasive imaging tests is used in terms of ability to identify or exclude luminal stenosis, often compared with invasive CAG as reference standard. Yet, in clinical practice the primary aim of is rather to assess the origin of symptoms and the risk of acute (major) cardiac events, so that both hopefully can be minimised (20) . Treatment strategies differed across studies with regards to revascularisation and optimal medical therapy. Yet, as has been shown in recent clinical trials, cardiac event rates with optimal medical therapy are quite low, even in patients with established CAD. The recent FAME 2 trial demonstrated no reduction in death or myocardial infarctions (MI) in patients with single or multi-vessel stable chest pain symptoms who underwent FFR-guided PCI of significant lesions, when added to OMT vs. OMT alone (21) . Also in the COURAGE by guest on June 9, 2016 http://ehjqcco.oxfordjournals.org/ Downloaded from trial, a lack of clinical benefit for death or MI when PCI of angiographically significant lesions was added to OMT in stable CAD patients was shown (22) . This supports the concept that the incremental use of preventive therapies will have a long-term beneficial effect. In addition, in the DIAD study patients with type 2 diabetes and no symptoms of CAD were randomly assigned to be screened with adenosine-stress radionuclide MPI or not to be screened. In this contemporary study population of patients with diabetes, the cardiac event rates were low and were not significantly reduced by MPI screening for myocardial ischaemia over 4.8 years (23) . Furthermore, the FACTOR-64 study in patients with type 1 or type 2 diabetes of at least 3 to 5 years' duration and without symptoms of CAD were included and randomly assigned to CAD screening with CTCA or to standard national guidelines-based optimal diabetes care. For this population it was shown that the use of CTCA to screen for CAD did not reduce the composite rate of all-cause mortality, nonfatal MI, or unstable angina requiring hospitalisation at 4 years (24) . Therefore, in patients with a low prior probability of CAD, it seems very unlikely that any testing will reduce cardiac events compared to no testing and appropriate risk factor modification. Moreover, for patients with stable CAD (excluding left main trunk disease and multi-vessel disease in diabetics), there are no randomised trials that support revascularisation to reduce hard cardiovascular end-points (cardiovascular death or MI). Therefore, unless these patients have limiting angina despite medical therapy, these revascularisations may be unnecessary (this is the so-called oculostenotic reflex).
Furthermore, in an analysis of the National Cardiovascular Data Registry (NCDR) in patients undergoing elective CAG, it was found that in 70% of the patients undergoing invasive CAG after CTCA had obstructive disease, which represents more than 50% improvement in identifying patients with obstructive disease compared to any functional test (i.e. xECG, SE, and CMRI) (P <.001) (25).
Based on these results the PROMISE trial (26) was undertaken, in order to provide a snapshot of realworld care for patients with suspicion of CAD. The most remarkable finding in the PROMISE trial was the diagnostic performance of CTCA over functional testing to identify obstructive CAD, i.e. 71.2% of patients undergoing invasive CAG after CTCA had obstructive disease compared to only 47.5% of functional test group patients (27). These numbers are remarkably similar to the NCDR data. This is crucial information as we attempt to properly stratify chest pain patients based on symptoms, with revascularisation and proper diagnosis of angina hanging in the balance (25). Couched in those terms, the sensitivity and specificity of non-invasive tests, particularly the functional ones which do not demonstrate stenosis directly, in relation to an angiographic standard may not be the best outcome parameter to use in economic modelling. Furthermore, although the results of PROMISE demonstrated better diagnostic accuracy of CTCA, it also demonstrated an obvious advantage of an anatomic approach, allowing more preventive therapies to be applied. Yet, in stable chest pain, there is no improvement in outcomes in the first year of statin or aspirin use, but as time progresses, the event curves in multiple studies diverge. This was impressively demonstrated in a second large scale study published simultaneously to PROMISE called SCOT-HEART assessing CTCA in patients with suspected angina due to CAD (28). In SCOT-HEART patients with suspected CAD were randomised to receive either only standard workup (in most cases, functional testing) or standard workup plus CTCA. In this trial, CTCA reclassified the diagnosis of CAD in 27% of the patients, and the diagnosis of angina due to CAD in 23% of patients (standard of care respectively 1% and 1%; P<.0001). This changed planned investigations (15% vs. 1%, P<.0001) and treatments (23% vs. 5%, P<.0001). Three year follow-up in SCOT-HEART demonstrated that the cardiovascular event rate was reduced by 50% in the CTCA group (28).
Furthermore, analyses were performed for several different countries including USA, UK, Australia and countries in Europe and Asia. Health care costs vary considerably across countries. In addition, and the threshold willingness-to-pay ranged from £10.000-€80.000/QALY. In this respect we recognise that diagnostic strategies and treatment decisions may also vary across countries.
Significant variations in diagnostic strategies between European and the United States are well documented and may be related to differences in health care systems, access to testing technologies, and risk tolerance (29) (30) (31) . Furthermore, a wide range of different combinations of imaging strategies (46) it was demonstrated that strategies using MPI were cheaper and equally effective when compared with strategies that did not use MPI, both for the cost of diagnosis and for overall 2-year management costs; the 2-year patient outcome was the same.
Sharples et al. (47) randomised 898 patients to SPECT, SE, CMRI, or direct CAG, and found SPECT to be as useful as immediate CAG with similar costs. At last, it is not necessarily clear in the current iteration that NICE guidance recommends risk assessment to direct choice of investigation of patients with stable chest pain and advocates CTCA at any rate rather than functional testing. Yet, many people in the low to intermediate probability group of having obstructive CAG will not have a calcium by guest on June 9, 2016 http://ehjqcco.oxfordjournals.org/ Downloaded from score of zero and will therefore go to CTCA directly, but when the prior probability is high enough they will go directly to CAG (12) .
Furthermore, the prior probability of CAD differed widely across studies ranging from 1%-90%. Yet, research has shown that clinical estimates of prior probability are grossly overinflated in real world application. For example, in the CONFIRM CT registry, the actual prevalence of obstructive CAD in patients with typical or atypical angina across the range of prior probabilities was only 20-50% of that predicted by the traditional Pryor approach (48) . Irrespective of age, sex, risk factors and the typicality of angina, no patient group had an observed prevalence of obstructive CAD >60%. Other studies have also shown that most patients who undergo invasive CAG after ischaemia testing have non-obstructive or normal arteries (49) . Therefore, in real life, the group of patients for whom direct CAG is cost-effective compared with CTCA may actually not exist. Interestingly, as in the case of the main population of the EVINCI study, traditional criteria for calculating prior probability overestimated the prevalence of haemodynamically significant CAD by 37% (50).
Limitations of this study
Our study has several limitations. First, although we carefully developed a search strategy, the search strategy could have missed possible relevant articles. Second, the review is based solely on published papers, and is thus restricted to the level of detail reported in the original papers. Third, studies evaluating CTCA based strategies were overrepresented in this systematic review. Studies evaluating a strategy of no testing were underrepresented. In addition, even though xECG and PET were included in some studies, these testing strategies have also been underrepresented. This may have biased the results presented in this systematic review. Fourth, most diagnostic accuracy studies suffer from referral bias. This may have distorted the diagnostic test characteristics used in the published cost-effectiveness analyses, which in turn diminishes the comparability and generalisability of the included cost-effectiveness studies. Further, all studies except three used CAG alone as the reference standard, whereas over the past years, CAG is increasingly used in combination with functional testing using catheter-based FFR for determining significance of stenosis. Finally, this systematic review is based on cost-effectiveness literature about stable chest pain patients, and the results should not be extrapolated to other settings, such as the diagnostic evaluation of patients presenting with acute chest pain.
Implications for clinical practice
The results of this systematic review suggest that for patients with a low to intermediate prior probability of having significant CAD, the optimal (sequence of) diagnostic imaging tests remains uncertain.
Although CTCA is gaining acceptance as a tool in the initial diagnostic approach of patients with low to intermediate prior probability of CAD, it is unlikely that the test will completely replace functional or invasive testing since this is still commonly used in patients presenting with a prior probability ≥50%. Furthermore, CTCA and CAG assess anatomic CAD stenosis, but do not assess the functional significance of coronary lesions. As a result, there is a potential for stenoses seen on CTCA and CAG that are not flow limiting, and therefore may require further evaluation with functional testing.
Functional testing should therefore be regarded as incremental to anatomical imaging in order to determine the clinical significance of stenosis, and the potential benefit of revascularisation and prognosis. Functional testing may be performed using xECG, SE, SPECT, PET, CMRI, CTCA-based FRR estimation or catheter-based invasive FFR measurement, the latter being the current reference standard test. In the future CTCA may allow the assessment of ischaemia using perfusion techniques or virtual FFR measurement, however, these are not yet established procedures. The role of functional testing for less severe stenoses is unclear: in such cases, the results of functional tests may guide the intensity of medical therapy, lifestyle interventions and the frequency of follow up visits. In this respect, more randomised clinical trials and cost-effectiveness research is needed.
In line with a previously performed systematic overview (51), the current systematic review highlights the importance of risk stratification based on prior probability to guide imaging decisions.
Ideally, the prior probability is estimated using a risk calculator that incorporates patient characteristics, medical history, risk factors and previous diagnostic test findings (11) . At each stage of the diagnostic workup process, new findings are included in the calculator in order to revise the probability which is then used to make the next workup decision. This leads to an individualised and integrated approach, consistent with the current focus on personalised medicine.
Conclusions
In conclusion, the results from this study suggest that CTCA as an initial gatekeeper imaging test is cost-effective under varying assumptions in patients presenting with stable chest pain with a low to intermediate prior probability of CAD. Yet, as seen in the SPARC registry and the PROMISE trial, the limitations of anatomical imaging raise concern that an over-reliance on coronary anatomy may result in excessive invasive CAGs and that the 'oculostenotic reflex' will increase revascularisation procedures. In addition, as has been seen in recent clinical trials (COURAGE, DIAD, FACTOR-64, FAME2, PROMISE), cardiac event rates with optimal medical therapy, even in patients with established CAD, are quite low. Therefore, in low risk patients with suspected CAD, it seems very unlikely that any testing will reduce cardiac events when compared to no testing and appropriate risk factor modification. Thus, no testing is likely more cost-effective than any imaging strategy in low risk patients. However, a strategy of no testing was underrepresented in the included studies. Therefore, in order to be able to firmly conclude that CTCA is the preferred strategy in low risk patients, a randomised trial (with economic sub-studies) comparing CTCA to a no testing strategy in low risk patients would be helpful. Further, the results from this study suggest SE or SPECT to be costeffective strategies if functional testing is required in patients presenting with stable chest pain with an intermediate prior probability of CAD. However, PET scanning and xECG have not been studied as intensely as other non-invasive functional testing strategies, and should therefore also be evaluated carefully in larger studies to assess its impact on clinical and economical outcomes. For patients presenting with stable chest pain with a high prior probability the results from this study suggest direct CAG to be the most cost-effective initial strategy. Yet, studies have shown that clinical estimates of prior probability are grossly overinflated in real world application. Therefore, in real life, the group of patients for whom direct CAG is cost-effective compared with CTCA may not actually exist. For this reason, although this study provides a summary of published economic evaluations in the form of a quick reference and allows for easy comparison, the results should be seen as a spur to further research rather than as providing definitive conclusions. Further studies are needed to compare the cost-effectiveness of alternative non-invasive testing approaches, including a no-testing strategy, for patients with stable chest pain symptoms suggestive of CAD. 
